Glycobiology and schizophrenia: a biological hypothesis emerging from genomic research

Robert G. Mealer,Sarah E. Williams,Mark J. Daly,Edward M. Scolnick,Richard D. Cummings,Jordan W. Smoller
DOI: https://doi.org/10.1038/s41380-020-0753-1
IF: 11
2020-05-06
Molecular Psychiatry
Abstract:Advances in genomics are opening new windows into the biology of schizophrenia. Though common variants individually have small effects on disease risk, GWAS provide a powerful opportunity to explore pathways and mechanisms contributing to pathophysiology. Here, we highlight an underappreciated biological theme emerging from GWAS: the role of glycosylation in schizophrenia. The strongest coding variant in schizophrenia GWAS is a missense mutation in the manganese transporter <i>SLC39A8</i>, which is associated with altered glycosylation patterns in humans. Furthermore, variants near several genes encoding glycosylation enzymes are unambiguously associated with schizophrenia: <i>FUT9</i>, <i>MAN2A1</i>, <i>TMTC1</i>, <i>GALNT10</i>, and <i>B3GAT1</i>. Here, we summarize the known biological functions, target substrates, and expression patterns of these enzymes as a primer for future studies. We also highlight a subset of schizophrenia-associated proteins critically modified by glycosylation including glutamate receptors, voltage-gated calcium channels, the dopamine D2 receptor, and complement glycoproteins. We hypothesize that common genetic variants alter brain glycosylation and play a fundamental role in the development of schizophrenia. Leveraging these findings will advance our mechanistic understanding of disease and may provide novel avenues for treatment development.
biochemistry & molecular biology,neurosciences,psychiatry
What problem does this paper attempt to address?